{"id":50878,"date":"2026-08-04T17:00:00","date_gmt":"2026-08-04T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=0ce609071aa37ddf2ba7179b7ad0dbd7"},"modified":"2026-08-04T17:00:00","modified_gmt":"2026-08-04T15:00:00","slug":"altasciences-completes-expansion-of-research-and-development-laboratory-in-harleysville-pennsylvania","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=50878","title":{"rendered":"Altasciences Completes Expansion of Research and Development Laboratory in Harleysville, Pennsylvania"},"content":{"rendered":"

LAVAL, Qu\u00e9bec--(BUSINESS WIRE)--#Altasciences<\/a>--Altasciences<\/a> is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space.<\/p><\/a><\/a><\/a><\/a>

\nThe expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scientific disciplines.<\/p>

\n\u201cWith this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey,\u201d said Anuji Abraham, Senior Director, Pharmaceutical Development, CDMO Services, Altasciences. \u201cThis enhances continuity across nonclinical and clinical programs, helping clients navigate key development milestones more efficiently and effectively.\u201d<\/p>

\nThe enhanced laboratory supports phase-appropriate, target product profile (TPP)-driven formulation screening, tailored to both therapeutic areas and routes of administration while remaining agnostic to both. Capabilities include formulation development for small molecules, peptides, and complex modalities, as well as non-GLP and GLP toxicology samples for nonclinical studies.<\/p>

\nAdvanced screening models and integrated analytical testing support nonclinical and clinical readiness, in addition to real-time formulation decisions. By operating in a non-GLP R&D environment, clients will gain flexibility to design and optimize their products before transitioning into regulated studies.<\/p>

\n\u201cThis expansion is not just about building additional space,\u201d said Robert Sabelli, Co-Chief Operating Officer, Altasciences. \u201cBy continuing to invest in our team, we are growing our scientific talent and connecting our capabilities earlier in the development cycle to better support our clients\u2014and ultimately, the patients they serve.\u201d<\/p>

\nAbout Altasciences<\/b><\/p>

\nAltasciences<\/a> is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO\/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across nonclinical<\/a>, clinical<\/a>, bioanalytical<\/a>, and formulation, and formulation and manufacturing services<\/a>. Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept\u2014helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence. To learn more about Altasciences, visit altasciences.com<\/a>.<\/p> Contacts<\/b>

\nJulie-Ann Cabana\nAltasciences<\/strong>media@altasciences.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LAVAL, Qu\u00e9bec–(BUSINESS WIRE)–#Altasciences–Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square fe…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-50878","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/50878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50878"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/50878\/revisions"}],"predecessor-version":[{"id":50879,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/50878\/revisions\/50879"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}